Form 4: Structure Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Xichen Lin, CHIEF SCIENTIFIC OFFICER of Structure Therapeutics Inc., sold 7,878 shares of common stock on July 14, 2026.
Summary
- Option exercise/conversion: acquired 23,634 Ordinary Shares at $0.34 ($8,036) on July 14, 2026; holds 252,594 after (Direct).
- Conversion of derivative: disposed of 23,634 Ordinary Shares on July 14, 2026; holds 228,960 after (Direct).
- Option exercise/conversion: disposed of 23,634 Share Option (right to buy) on July 14, 2026; holds 166,532 after (Direct).
- Conversion of derivative: acquired 7,878 American Depositary Shares on July 14, 2026; holds 7,878 after (Direct).
- Open-market sale: disposed of 6,278 American Depositary Shares at $50.80 ($318,895) on July 14, 2026; holds 1,600 after (Direct).
- Open-market sale: disposed of 1,600 American Depositary Shares at $51.71 ($82,734) on July 14, 2026 (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $401,629 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Xichen Lin — Officer (CHIEF SCIENTIFIC OFFICER)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-14 | Option exercise/conversion | Ordinary Shares | 23,634 | $0 | $8.0K | 252,594 |
| 2026-07-14 | Conversion of derivative | Ordinary Shares | 23,634 | — | — | 228,960 |
| 2026-07-14 | Option exercise/conversion | Share Option (right to buy) | 23,634 | — | — | 166,532 |
| 2026-07-14 | Conversion of derivative | American Depositary Shares | 7,878 | — | — | 7,878 |
| 2026-07-14 | Open-market sale | American Depositary Shares | 6,278 | $51 | $318.9K | 1,600 |
| 2026-07-14 | Open-market sale | American Depositary Shares | 1,600 | $52 | $82.7K | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-14 | Option exercise/conversion (23,634 shares) |
| 2026-07-14 | Conversion of derivative (23,634 shares) |
| 2026-07-14 | Option exercise/conversion (23,634 shares) |
| 2026-07-14 | Conversion of derivative (7,878 shares) |
| 2026-07-14 | Open-market sale (6,278 shares) |
| 2026-07-14 | Open-market sale (1,600 shares) |
Keywords
insider transaction, Form 4, GPCR, Structure Therapeutics Inc., bearish, Xichen Lin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.